(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Sarepta Therapeutics, Aspen Group, and 3D Systems.

Rank	Financial Asset	Price	Change	Updated (EST)
1	Sarepta Therapeutics (SRPT)	146.54	19.99%	2023-03-01 15:12:11
2	Aspen Group (ASPU)	0.19	16.92%	2023-03-01 15:16:52
3	3D Systems (DDD)	11.09	13.28%	2023-03-01 15:57:28
4	3D Systems (DDD)	11.09	13.28%	2023-03-01 15:57:28
5	RadNet (RDNT)	23.58	12.04%	2023-03-01 01:17:08
6	Spectrum Pharmaceuticals (SPPI)	0.86	10.48%	2023-03-01 13:42:17
7	Recon Technology, Ltd. (RCON)	2.05	10.22%	2023-03-01 01:11:08
8	Zai Lab (ZLAB)	40.38	8.68%	2023-03-01 15:53:55
9	DAQO New Energy (DQ)	47.21	6.85%	2023-03-01 15:57:38
10	Trip.com (TCOM)	37.72	6.12%	2023-03-01 15:50:00

The three biggest losers today are Novavax, Virgin Galactic, and SmileDirectClub.

Rank	Financial Asset	Price	Change	Updated (EST)
1	Novavax (NVAX)	6.85	-26.03%	2023-03-01 15:59:18
2	Virgin Galactic (SPCE)	4.74	-17.51%	2023-03-01 15:52:19
3	SmileDirectClub (SDC)	0.52	-13.42%	2023-03-01 15:33:53
4	Clean Energy Fuels (CLNE)	4.90	-12.59%	2023-03-01 15:54:59
5	First Horizon National (FHN)	22.25	-10.19%	2023-03-01 15:58:33
6	Castle Biosciences (CSTL)	22.84	-9.29%	2023-03-01 15:47:55
7	Groupon (GRPN)	6.84	-8.85%	2023-03-01 15:57:19
8	Marathon (MARA)	6.49	-8.66%	2023-03-01 15:58:32
9	Weibo (WB)	19.00	-8.15%	2023-03-01 15:46:50
10	MicroVision (MVIS)	2.36	-8.01%	2023-03-01 15:58:58

Winners today

1. Sarepta Therapeutics (SRPT) – 19.99%

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Sarepta Therapeutics rising 19.99% to $146.54 on Wednesday while NASDAQ dropped 0.66% to $11,379.48.

Earnings Per Share

As for profitability, Sarepta Therapeutics has a trailing twelve months EPS of $-8.5.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -107.16%.

Volume

Today’s last reported volume for Sarepta Therapeutics is 5885660 which is 537.27% above its average volume of 923564.

Yearly Top and Bottom Value

Sarepta Therapeutics’s stock is valued at $146.54 at 16:32 EST, under its 52-week high of $152.28 and way above its 52-week low of $61.28.

More news about Sarepta Therapeutics.

2. Aspen Group (ASPU) – 16.92%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group jumping 16.92% to $0.19 on Wednesday, following the last session’s upward trend. NASDAQ slid 0.66% to $11,379.48, after three consecutive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.383.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.28%.

More news about Aspen Group.

3. 3D Systems (DDD) – 13.28%

3D Systems Corporation, through its subsidiaries, provides 3D printing and digital manufacturing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers 3D printers, such as stereolithography, selective laser sintering, direct metal printing, multi jet printing, color jet printing, and extrusion and SLA based bioprinting that transform digital data input generated by 3D design software, computer aided design (CAD) software, or other 3D design tools into printed parts. It also develops, blends, and markets various print materials, such as plastic, nylon, metal, composite, elastomeric, wax, polymeric dental, and bio-compatible materials. In addition, the company provides digital design tools, including software, scanners, and haptic devices, as well as solutions for product design, simulation, mold and die design, 3D scan-to-print, reverse engineering, production machining, metrology, and inspection and manufacturing workflows under the Geomagic brand. Further, it offers 3D Sprint and 3DXpert, a proprietary software to prepare and optimize CAD data and manage the additive manufacturing processes, which provides automated support building and placement, build platform management, print simulation, and print queue management; and Bioprint Pro, a software solution that allows researchers to design and bioprint repeatable experiments. Additionally, the company provides maintenance and training services; manufacturing services; and software and precision healthcare services. It primarily serves companies and small and midsize businesses in medical, dental, automotive, aerospace, durable good, government, defense, technology, jewelry, electronic, education, consumer good, energy, biotechnology, and other industries through direct sales force, channel partners, and appointed distributors. 3D Systems Corporation was founded in 1986 and is headquartered in Rock Hill, South Carolina.

NYSE ended the session with 3D Systems jumping 13.28% to $11.09 on Wednesday, after four successive sessions in a row of losses. NYSE rose 0.07% to $15,439.55, after three sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

3d systems (ddd) reports Q4 loss, tops revenue estimatesWhile 3D Systems has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

Earnings Per Share

As for profitability, 3D Systems has a trailing twelve months EPS of $-1.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.94%.

Yearly Top and Bottom Value

3D Systems’s stock is valued at $11.09 at 16:32 EST, way below its 52-week high of $20.51 and way above its 52-week low of $7.02.

More news about 3D Systems.

4. 3D Systems (DDD) – 13.28%

NYSE ended the session with 3D Systems jumping 13.28% to $11.09 on Wednesday while NYSE rose 0.07% to $15,439.55.

3d systems (ddd) reports Q4 loss, tops revenue estimatesWhile 3D Systems has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

Earnings Per Share

As for profitability, 3D Systems has a trailing twelve months EPS of $-1.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.94%.

Volume

Today’s last reported volume for 3D Systems is 3489210 which is 166.24% above its average volume of 1310520.

More news about 3D Systems.

5. RadNet (RDNT) – 12.04%

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

NASDAQ ended the session with RadNet jumping 12.04% to $23.58 on Wednesday, after two sequential sessions in a row of gains. NASDAQ dropped 0.66% to $11,379.48, after three consecutive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Radnet foresees strong financial and operational performance in 2023The company we are profiling today is one of the key players in the Diagnostic Imaging Services Market – RadNet Inc. (RDNT)., Under the EBCD program, RadNet is offering novel AI-enhanced mammography services to women in conjunction with its annual breast cancer screening exams for an additional fee.

Earnings Per Share

As for profitability, RadNet has a trailing twelve months EPS of $0.11.

PE Ratio

RadNet has a trailing twelve months price to earnings ratio of 214.41. Meaning, the purchaser of the share is investing $214.41 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.51%.

Previous days news about RadNet

Radnet (rdnt) misses Q4 earnings estimates. According to Zacks on Tuesday, 28 February, "While RadNet has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"

More news about RadNet.

6. Spectrum Pharmaceuticals (SPPI) – 10.48%

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.

NASDAQ ended the session with Spectrum Pharmaceuticals jumping 10.48% to $0.86 on Wednesday while NASDAQ slid 0.66% to $11,379.48.

Earnings Per Share

As for profitability, Spectrum Pharmaceuticals has a trailing twelve months EPS of $-1.293.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -184.06%.

More news about Spectrum Pharmaceuticals.

7. Recon Technology, Ltd. (RCON) – 10.22%

Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other hardware related to oilfield production and management, and transportation; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as enhancing techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; and oily sludge disposal solutions. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Recon Technology, Ltd. rising 10.22% to $2.05 on Wednesday, after two successive sessions in a row of gains. NASDAQ slid 0.66% to $11,379.48, after three successive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Recon Technology, Ltd. has a trailing twelve months EPS of $0.45.

PE Ratio

Recon Technology, Ltd. has a trailing twelve months price to earnings ratio of 4.56. Meaning, the purchaser of the share is investing $4.56 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.92%.

Yearly Top and Bottom Value

Recon Technology, Ltd.’s stock is valued at $2.05 at 16:32 EST, below its 52-week high of $2.07 and way above its 52-week low of $0.50.

More news about Recon Technology, Ltd..

8. Zai Lab (ZLAB) – 8.68%

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zai Lab jumping 8.68% to $40.38 on Wednesday, following the last session’s upward trend. NASDAQ dropped 0.66% to $11,379.48, after three sequential sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-3.46.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.05%.

Volatility

Zai Lab’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.00%, a negative 1.28%, and a positive 4.13%.

Zai Lab’s highest amplitude of average volatility was 1.19% (last week), 2.62% (last month), and 4.13% (last quarter).

Yearly Top and Bottom Value

Zai Lab’s stock is valued at $40.38 at 16:32 EST, way under its 52-week high of $56.06 and way above its 52-week low of $20.98.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is a negative 22.8% and positive 48.8% for the next.

More news about Zai Lab.

9. DAQO New Energy (DQ) – 6.85%

Daqo New Energy Corp., together with its subsidiaries, manufactures and sells polysilicon to photovoltaic product manufactures in the People's Republic of China. Its products are used in ingots, wafers, cells, and modules for solar power solutions. The company was formerly known as Mega Stand International Limited and changed its name to Daqo New Energy Corp. in August 2009. Daqo New Energy Corp. was founded in 2006 and is based in Shanghai, the People's Republic of China.

NYSE ended the session with DAQO New Energy jumping 6.85% to $47.21 on Wednesday while NYSE rose 0.07% to $15,439.55.

Earnings Per Share

As for profitability, DAQO New Energy has a trailing twelve months EPS of $1.7.

PE Ratio

DAQO New Energy has a trailing twelve months price to earnings ratio of 27.8. Meaning, the purchaser of the share is investing $27.8 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 52.23%.

Sales Growth

DAQO New Energy’s sales growth is 149.7% for the present quarter and negative 21.8% for the next.

Moving Average

DAQO New Energy’s worth is above its 50-day moving average of $43.60 and way under its 200-day moving average of $53.77.

Yearly Top and Bottom Value

DAQO New Energy’s stock is valued at $47.21 at 16:32 EST, way below its 52-week high of $77.18 and way higher than its 52-week low of $32.20.

Revenue Growth

Year-on-year quarterly revenue growth grew by 108.2%, now sitting on 4.14B for the twelve trailing months.

More news about DAQO New Energy.

10. Trip.com (TCOM) – 6.12%

Trip.com Group Limited operates as a travel service provider for accommodation reservation, transportation ticketing, packaged tours and in-destination, corporate travel management, and other travel-related services in China and internationally. The company acts as an agent for hotel-related transactions and selling air tickets, as well as provides train, long-distance bus, and ferry tickets; travel insurance products, such as flight delay, air accident, and baggage loss coverage; and air-ticket delivery, online check-in and seat selection, express security screening, real-time flight status tracker, and airport VIP lounge services. It also provides independent leisure travelers bundled packaged-tour products comprising group, semi-group, and customized and packaged tours with various transportation arrangements, such as air, cruise, bus, and car rental services. In addition, the company offers integrated transportation and accommodation services; destination transportation and ticket, activity, insurance, visa, and tour guide services; user support, supplier management, and customer relationship management services; and in-destination products and services. Further, it provides its corporate clients with business visit, incentive trip, meeting and conference, travel data collection and analysis, industry benchmark, cost saving analysis, and travel management solutions; and Corporate Travel Management System, an online platform that integrates information management, online booking and authorization, online enquiry, and travel reporting systems. Additionally, the company offers online advertising and financial services. It operates under the Ctrip, Qunar, Trip.com, and Skyscanner brands. The company was formerly known as Ctrip.com International, Ltd. and changed its name to Trip.com Group Limited in October 2019. Trip.com Group Limited was founded in 1999 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with Trip.com rising 6.12% to $37.72 on Wednesday while NASDAQ dropped 0.66% to $11,379.48.

Earnings Per Share

As for profitability, Trip.com has a trailing twelve months EPS of $0.31.

PE Ratio

Trip.com has a trailing twelve months price to earnings ratio of 121.69. Meaning, the purchaser of the share is investing $121.69 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.44%.

More news about Trip.com.

Losers Today

1. Novavax (NVAX) – -26.03%

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax dropping 26.03% to $6.85 on Wednesday, following the last session’s upward trend. NASDAQ slid 0.66% to $11,379.48, after three sequential sessions in a row of losses, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Novavax has a trailing twelve months EPS of $-7.27.

Volume

Today’s last reported volume for Novavax is 22496600 which is 213.36% above its average volume of 7179080.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is 90% and a drop 158.6% for the next.

Previous days news about Novavax

: Novavax stock sheds a quarter of its value after hours following revenue miss. According to MarketWatch on Tuesday, 28 February, "While our current cash flow forecast for the one-year going concern look-forward period estimates that we have sufficient capital available to fund operations, this forecast is subject to significant uncertainty, including as it relates to 2023 revenue, funding from the U.S. government, and pending arbitration," Novavax said in a…"

More news about Novavax.

2. Virgin Galactic (SPCE) – -17.51%

Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico. Virgin Galactic Holdings, Inc. was a former subsidiary of Virgin Orbit Holdings, Inc.

NYSE ended the session with Virgin Galactic dropping 17.51% to $4.74 on Wednesday while NYSE rose 0.07% to $15,439.55.

Earnings Per Share

As for profitability, Virgin Galactic has a trailing twelve months EPS of $-1.552.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.97%.

Sales Growth

Virgin Galactic’s sales growth is negative 89.5% for the present quarter and negative 48.1% for the next.

Volatility

Virgin Galactic’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.64%, a negative 0.19%, and a positive 4.16%.

Virgin Galactic’s highest amplitude of average volatility was 2.11% (last week), 4.86% (last month), and 4.16% (last quarter).

More news about Virgin Galactic.

3. SmileDirectClub (SDC) – -13.42%

SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a doctor, and monitoring through completion of their treatment with a network of approximately 250 licensed orthodontists and general dentists through its teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.

NASDAQ ended the session with SmileDirectClub sliding 13.42% to $0.52 on Wednesday while NASDAQ dropped 0.66% to $11,379.48.

Earnings Per Share

As for profitability, SmileDirectClub has a trailing twelve months EPS of $-2.334.

Yearly Top and Bottom Value

SmileDirectClub’s stock is valued at $0.52 at 16:32 EST, way below its 52-week high of $3.10 and way above its 52-week low of $0.32.

Volume

Today’s last reported volume for SmileDirectClub is 2793580 which is 3.28% below its average volume of 2888380.

Sales Growth

SmileDirectClub’s sales growth is negative 28.2% for the present quarter and negative 27.2% for the next.

More news about SmileDirectClub.

4. Clean Energy Fuels (CLNE) – -12.59%

Clean Energy Fuels Corp. provides natural gas as an alternative fuel for vehicle fleets and related fueling solutions, primarily in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. As of December 31, 2021, the company served approximately 1,000 fleet customers operating approximately 48,000 vehicles; and owned, operated, or supplied approximately 548 fueling stations in 42 states in the United States and 25 fueling stations in Canada. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.

NASDAQ ended the session with Clean Energy Fuels dropping 12.59% to $4.90 on Wednesday while NASDAQ dropped 0.66% to $11,379.48.

Clean energy fuels (clne) lags Q4 earnings estimatesWhile Clean Energy Fuels has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

Earnings Per Share

As for profitability, Clean Energy Fuels has a trailing twelve months EPS of $-0.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.69%.

Volatility

Clean Energy Fuels’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.01%, a negative 0.18%, and a positive 2.46%.

Clean Energy Fuels’s highest amplitude of average volatility was 1.70% (last week), 2.18% (last month), and 2.46% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 66.7% and positive 80% for the next.

Yearly Top and Bottom Value

Clean Energy Fuels’s stock is valued at $4.90 at 16:32 EST, way under its 52-week high of $8.65 and way above its 52-week low of $4.02.

Volume

Today’s last reported volume for Clean Energy Fuels is 8258910 which is 309.34% above its average volume of 2017580.

More news about Clean Energy Fuels.

5. First Horizon National (FHN) – -10.19%

First Horizon Corporation operates as the bank holding company for First Horizon Bank that provides various financial services. The company operates through three segments: Regional Banking, Specialty Banking, and Corporate. It offers general banking services for consumers, businesses, financial institutions, and governments. The company also underwrites bank-eligible securities and other fixed-income securities eligible for underwriting by financial subsidiaries; sells loans and derivatives; and offers advisory services. In addition, it offers various services, such as mortgage banking; title insurance and loan-closing; brokerage; correspondent banking; nationwide check clearing and remittance processing; trust, fiduciary, and agency; equipment finance; and investment and financial advisory services. Further, the company sells mutual fund and retail insurance products; and credit cards. It operates approximately 500 banking offices in 22 states under the First Horizon Bank brand; and 400 banking centers in 12 states under the FHN Financial brand in the United States. The company was formerly known as First Horizon National Corporation and changed its name to First Horizon Corporation in November 2020. First Horizon Corporation was founded in 1864 and is headquartered in Memphis, Tennessee.

NYSE ended the session with First Horizon National sliding 10.19% to $22.25 on Wednesday, following the last session’s upward trend. NYSE jumped 0.07% to $15,439.55, after three consecutive sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, First Horizon National has a trailing twelve months EPS of $2.08.

PE Ratio

First Horizon National has a trailing twelve months price to earnings ratio of 10.68. Meaning, the purchaser of the share is investing $10.68 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.7%.

Sales Growth

First Horizon National’s sales growth is 25.4% for the present quarter and 20.6% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 3.1%, now sitting on 3.11B for the twelve trailing months.

More news about First Horizon National.

6. Castle Biosciences (CSTL) – -9.29%

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

NASDAQ ended the session with Castle Biosciences dropping 9.29% to $22.84 on Wednesday, after four consecutive sessions in a row of gains. NASDAQ slid 0.66% to $11,379.48, after three successive sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Castle Biosciences has a trailing twelve months EPS of $-1.24.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.86%.

More news about Castle Biosciences.

7. Groupon (GRPN) – -8.85%

Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with Groupon dropping 8.85% to $6.84 on Wednesday while NASDAQ fell 0.66% to $11,379.48.

Earnings Per Share

As for profitability, Groupon has a trailing twelve months EPS of $-10.07.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -121.5%.

Volatility

Groupon’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.76%, a negative 0.86%, and a positive 3.92%.

Groupon’s highest amplitude of average volatility was 1.88% (last week), 3.38% (last month), and 3.92% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 322.2% and positive 91.2% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Groupon’s stock is considered to be oversold (<=20).

More news about Groupon.

8. Marathon (MARA) – -8.66%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines cryptocurrencies with a focus on the blockchain ecosystem and the generation of digital assets in United States. As of December 31, 2021, it had approximately 8,115 bitcoins, which included the 4,794 bitcoins held in the investment fund. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.

NASDAQ ended the session with Marathon falling 8.66% to $6.49 on Wednesday while NASDAQ slid 0.66% to $11,379.48.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-0.13.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.77%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 75.5%, now sitting on 149.61M for the twelve trailing months.

Yearly Top and Bottom Value

Marathon’s stock is valued at $6.49 at 16:32 EST, way under its 52-week high of $32.74 and way higher than its 52-week low of $3.11.

More news about Marathon.

9. Weibo (WB) – -8.15%

Weibo Corporation, through its subsidiaries, operates as a social media platform for people to create, distribute, and discover content in the People's Republic of China. It operates in two segments, Advertising and Marketing Services; and Value-Added Services. The company offers discovery products to help users discover content on its platform; self-expression products that enable its users to express themselves on its platform; and social products to promote social interaction between users on its platform. It also provides advertising and marketing solutions, such as social display advertisements; and promoted marketing offerings, such as Fans Headline and Weibo Express, as well as promoted trends and search products that appear alongside user's trends discovery and search behaviors. In addition, the company offers products, such as trends, search, video/live streaming, and editing tools; content customization, copyright contents pooling, and user interaction development; and search list recommendation, trends list recommendation, and Weibo app opening advertisements. Further, it provides back-end management, traffic support, and product solutions to MCNs, unions, and e-commerce partners; open application platform for other app developers that allows users to log into third-party applications with their Weibo account for sharing third-party content on its platform; and Weibo Wallet, a product that enables platform partners to conduct interest generation activities on Weibo, such as handing out red envelops and coupons. The company was formerly known as T.CN Corporation and changed its name to Weibo Corporation in 2012. The company was founded in 2009 and is headquartered in Beijing, China. Weibo Corporation is a subsidiary of Sina Corporation.

NASDAQ ended the session with Weibo sliding 8.15% to $19.00 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ slid 0.66% to $11,379.48, after three consecutive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Weibo has a trailing twelve months EPS of $1.38.

PE Ratio

Weibo has a trailing twelve months price to earnings ratio of 13.76. Meaning, the purchaser of the share is investing $13.76 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.2%.

Volatility

Weibo’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.58%, a negative 0.84%, and a positive 3.37%.

Weibo’s highest amplitude of average volatility was 0.78% (last week), 2.69% (last month), and 3.37% (last quarter).

Previous days news about Weibo

Is a surprise coming for weibo (wb) this earnings season?. According to Zacks on Tuesday, 28 February, "Investors are always looking for stocks that are poised to beat at earnings season and Weibo Corporation (WB Quick QuoteWB – Free Report) may be one such company. ", "That is because Weibo is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. "

More news about Weibo.

10. MicroVision (MVIS) – -8.01%

MicroVision, Inc. develops lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems, laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module that can support AR headsets; Interactive Display modules used in smart speakers and other devices; and Consumer Lidar used in smart home systems. In addition, it provides PicoP, a scanning technology that creates full color, high-contrast, and uniform image over the entire field-of-view from a small and thin module. Further, the company develops 1st generation long range lidar. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

NASDAQ ended the session with MicroVision falling 8.01% to $2.36 on Wednesday, following the last session’s upward trend. NASDAQ dropped 0.66% to $11,379.48, after three consecutive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, MicroVision has a trailing twelve months EPS of $-0.102.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -50.24%.

Moving Average

MicroVision’s value is under its 50-day moving average of $2.60 and way under its 200-day moving average of $3.62.

Sales Growth

MicroVision’s sales growth is negative 10.2% for the ongoing quarter and 14.3% for the next.

Yearly Top and Bottom Value

MicroVision’s stock is valued at $2.36 at 16:32 EST, way under its 52-week high of $5.96 and way higher than its 52-week low of $2.11.

Volatility

MicroVision’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.58%, a negative 1.00%, and a positive 3.58%.

MicroVision’s highest amplitude of average volatility was 2.58% (last week), 3.81% (last month), and 3.58% (last quarter).

More news about MicroVision.

Stay up to date with our winners and losers daily report